Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

Notice Regarding Dividends of Surplus (Increase in Dividend) and Changes to Dividend Policy

TOKYO, May 11, 2026 - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi) announced that at its Board of Directors meeting held on May 11, 2026, it resolved to submit a proposal for a dividend distribution (year-end dividend) with a record date of March 31, 2026, to the 5th Ordinary General Meeting of Shareholders to be held on June 24, 2026, and to change its dividend policy for FY2026, and thereafter as follows.

1. Dividends of surplus

(1) Details of the Dividend

	Amount Determined	Latest Dividend Forecast (Announced on May 12, 2025)	Previous Period Results
Reference Date	March 31, 2026	As above	March 31, 2025
Dividend per Share	33.00 yen	28.00 yen	30.00 yen
Total Amount of Dividends	937 million yen	—	850 million yen
Effective Date	June 25, 2026	—	June 25, 2025
Source of Dividends	Retained Earnings	—	Retained Earnings

(2) Reasons for Revision

The Company considers the return of profits to shareholders to be a key management priority. Regarding its dividend policy, the Company targets a consolidated dividend payout ratio of 30% for performance-linked profit distribution. Furthermore, the Company intends to maintain stable dividends while providing performance-linked profit distribution, with a minimum annual dividend of 30 yen per share.

Based on the policy described above, the Company plans to pay a year-end dividend of 33 yen per share for the current fiscal year. As a result, the annual dividend will be 60 yen per share when combined with the interim dividend of 27 yen, an increase of 5 yen per share compared to the previous fiscal year. Based on this, the consolidated dividend payout ratio is 31.4%.

(Reference) Dividend Forecast for FY2025

	Annual Dividend		
	End of Second Quarter	Fiscal Year-End	Total
Previous Forecast (Announced on May 12, 2025)	Yen 27.00	Yen 28.00	Yen 55.00
Revised Forecast		33.00	60.00
Actual Results	27.00		
Previous Period Results (FY2024)	25.00	30.00	55.00

2. Change in Dividend Policy

(1) Changes to the Dividend Policy

[Before the Change]

As a performance-linked profit distribution strategy, the Company indicates a consolidated dividend payout benchmark ratio of 30%. In addition, the Company's policy is to maintain stable dividends while providing performance-linked returns to shareholders, with a minimum annual dividend of 30 yen per share.

[After the Change]

As part of the performance-linked profit distribution strategy, the Company provides shareholder returns with a payout ratio of approximately 40% as a guideline. The Company aims to improve dividend levels in line with profit growth. In addition, to clearly demonstrate its commitment to returning profits to shareholders, the Company will introduce a progressive dividend policy (excluding special dividends) and, in principle, will not reduce dividends, thereby striving to maintain stable dividends.

(2) Reasons for Change

The Company considers the return of profits to shareholders to be a key management priority. In the Medium-Term Management Plan 2028, which will begin in FY2026, the Company will consider flexibly acquiring its own shares with a target total shareholder return ratio of 40%. Based on these policies, during this Medium-Term Management Plan period, the Company will revise its dividend policy by introducing a progressive dividend (excluding special dividends), with the aim of further enhancing shareholder returns and increasing the stability and predictability of dividends.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp